Current status of experimental therapeutics for prostate cancer

Cancer Letters

Volumn 266, Issue 2, 2008, Pages 116-134

  Moon, Chulso ^a   Park, Jong Chul ^a   Chae, Young Kwang ^a   Yun, Jin Han ^b   Kim, Saechul ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dong A University   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

Author keywords

Gene therapy; Hormonal refractory prostate cancer; Immunotherapy; Targeted therapy

Indexed keywords

A 177430; ACID PHOSPHATASE PROSTATE ISOENZYME; ANGIOSTATIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BEVACIZUMAB; CALCITRIOL; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIGALLOCATECHIN GALLATE; ERLOTINIB; ESTRAMUSTINE; EVEROLIMUS; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; LAPATINIB; OBLIMERSEN; PANITUMUMAB; PERTUZUMAB; PLACEBO; PREDNISONE; PRINOMASTAT; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN TYROSINE KINASE; PROVENGE; SORAFENIB; THROMBOCYTE FACTOR 4; TRASTUZUMAB; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC GENE THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG MEGADOSE; ELECTROPORATION; GENE EXPRESSION; GENE VECTOR; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SUICIDE GENE THERAPY; TUMOR CELL;

EID: 45049086542     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.065     Document Type: Review

References (110)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
2. Pirtskhalaishvili G., Hrebinko R.L., and Nelson J.B. The treatment of prostate cancer: an overview of current options. Cancer Pract. 9 (2001) 295-306
3. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351 (2004) 1513-1520
4. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351 (2004) 1502-1512
5. Patel P., Ashdown D., and James N. Is gene therapy the answer for prostate cancer?. Prostate Cancer Prostatic Dis. 7 Suppl. 1 (2004) S14-S19
6. Kay M.A., Holterman A.X., Meuse L., et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA 4Ig administration. Nat. Genet. 11 (1995) 191-197
7. Dai Y., Schwarz E.M., Gu D., Zhang W.W., Sarvetnick N., and Verma I.M. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92 (1995) 1401-1405
8. Li Y., Pong R.C., Bergelson J.M., Hall M.C., Sagalowsky A.I., Tseng C.P., Wang Z., and Hsieh J.T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59 (1999) 325-330
9. Miller C.R., Buchsbaum D.J., Reynolds P.N., Douglas J.T., Gillespie G.Y., Mayo M.G.Y., Raben M.S., and Curiel D.T. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58 (1998) 5738-5748
10. Fechner H., Wang X., Wang H., Jansen A., Pauschinger M., Scherubl H., Bergelson J.M., Schultheiss P., and Poller W. Trans-complementation of vector replication versus COXsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther. 7 (2000) 1954-1968
11. Cripe T.P., Dunphy E.J., Holub A.D., Saini A., Vasi N.H., Mahller Y.Y., Collins M.H., Snyder J.D., Krasnykh V., Curiel D.T., Wickham T.J., DeGregori J., Bergelson J.M., and Currier M.A. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61 (2001) 2953-2960
12. Miller N., and Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum. Gene Ther. 8 (1997) 803-815
13. Iqball S., Kingsman A., Kingsman S., and Naylor S. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther. 6 (1999) 1721-1727
14. Okegawa T., Li Y., Pong R.C., Bergelson J.M., Zhou J., and Hsieh T.J. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. 60 (2000) 5031-5036
15. Belldegrun A., Tso C.L., Zisman A., et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther. 8 (2001) 883-892
16. Cotten M., Wagner E., Zatloukal K., Phillips S., Curiel D.T., and Birnsteil M.L. High efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome disruption activity of defective or chemically inactivated adenovirus particles. Proc. Natl. Acad. Sci. USA 89 (1992) 6094-6098
17. Israeli R.S., Grob M., and Fair W.R. Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. Urol. Clin. North Am. 24 (1997) 439
18. Pang S., Dannull J., Kaboo R., et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 57 (1997) 495
19. Brookes D.E., Zandvliet D., Watt F., et al. Relative activity and specificity of promoters from prostate-expressed genes. Prostate 18 (1998) 35
20. Gotoh A., Ko S.C., Shirakawa T., et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. 160 (1998) 220
21. Spitzweg C., Zhang S., Bergert E.R., et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 59 (1999) 2136
22. Steiner M.S., Zhang Y., Carraher J., and Lu Y. In vivo expression of prostate-specific adenoviral vectors in a canine model. Cancer Gene Ther. 6 (1999) 456
23. Latham J.P., Searle P.F., Mautner V., et al. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 60 (2000) 334
24. O'Keefe D.S., Uchida A., Bacich D.J., et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 45 (2000) 149
25. Lee S.E., Jin R.J., Lee S.G., et al. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res. 20 (2000) 417
26. Lu Y., and Steiner M.S. Transcriptionally regulated adenoviruses for prostate-specific gene therapy. World J. Urol. 18 (2000) 93
27. Koeneman K.S., Kao C., Ko S.C., et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 18 (2000) 102
28. Aghi M., Hochberg F., and Breakefield X.O. Prodrug activation enzymes in cancer gene therapy. J. Gene Med. 2 (2000) 148-164
29. Lumniczky K., and Safrany G. Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect. Pathol. Oncol. Res. 12 (2006) 118-124
30. Hoganson D.K., Batra R.K., Olsen J.C., and Boucher R.C. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 56 (1996) 1315-1323
31. Herman J.R., Adler H.L., Aguilar-Cordova E., et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. 10 (1999) 1239
32. Shalev M., Kadmon D., Teh B.S., et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J. Urol. 163 (2000) 1747
33. Balaji K.C., Koul H., Mitra S., et al. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology 50 1007 (1997)
34. Steiner M.S., Anthony C.T., Lu Y., et al. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum. Gene Ther. 9 (1998) 747
35. Gleave M., Tolcher A., Miyake H., et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res. 5 (1999) 2891
36. Miyake H., Tolcher A., and Gleave M.E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 ligodeoxynucleotides. J. Natl. Cancer Inst. 92 (2000) 34
37. Ogiso Y., Sakai N., Watari H., et al. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Ther. 1 (1994) 403
38. Geiger T., Muller M., Monia B.P., et al. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin. Cancer Res. 3 (1997) 1179
39. Lee C.H., Liu M., Sie K.L., et al. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase alpha and topoisomerase II alpha in prostate cancer. Anticancer Res. 16 (1996) 1805
40. Moon C., Oh Y., and Roth J.A. Current status of gene therapy for lung cancer and head and neck cancer. Clin. Cancer Res. 9 (2003) 5055-5067
41. Small E.J., Carducci M.A., Burke J.M., et al. metastatic prostate cancer. Mol. Ther. 14 (2006) 107-117
42. Blackburn R.V., Galoforo S.S., Corry P.M., and Lee Y.J. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity. Int. J. Cancer 82 (1999) 293-297
43. Freytag S.O., Khil M., Stricker H., et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62 (2002) 4968-4976
44. Freytag S.O., Stricker H., Pegg J., et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63 (2003) 7497-7506
45. Freytag S.O., Stricker H., Peabody J., Pegg J., Paielli D., et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 15 (2007) 636-642
46. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277
47. O'Reilly M.S., Holmgren L., Chen C., et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2 (1996) 689
48. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., and Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285 (1999) 1926
49. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315
50. Sauter B.V., Martinet O., Zhang W.J., et al. Adenovirus mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA 97 (2000) 4802
51. Tanaka T., Manome Y., Wen P., et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3 (1997) 437
52. Li H., Griscelli F., Lindenmeyer F., et al. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum. Gene Ther. 10 (1999) 3045
53. Marcelli M., Cunningham G.R., Walkup M., et al. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 59 (1999) 382
54. Griffith T.S., Anderson R.D., Davidson B.L., et al. Adenoviral-mediated transfer of the TNF-related apoptosis inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J. Immunol. 165 (2000) 2886
55. Tepper R.I., and Mule J.J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5 (1994) 153
56. Sanda M.G., Ayyagari S.R., Jaffee E.M., et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151 (1994) 622
57. Vieweg J., Rosenthal F.M., Bannerji R., et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54 (1994) 1760
58. Melcher A., Gough M., Todryk S., et al. Apoptosis or necrosis for tumor immunotherapy: what's in a name?. J. Mol. Med. 77 (1997) 824
59. Bander N.H., Yao D., Liu H., et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33 (1997) 233
60. Kwon 35.E.D., Hurwitz A.A., Foster B.A., et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 8099
61. Sanda M.G., Restifo N.P., Walsh J.C., et al. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 87 (1995) 280
62. Nabel G.J., Chang A.E., Nabel E.G., et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum. Gene Ther. 5 (1994) 57
63. Dohring C., Angman L., Spagnoli G., et al. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer 57 (1994) 754
64. Dalgleish A. The case for therapeutic vaccines. Melanoma Res. 6 (1996) 5
65. Vile R.G., Nelson J.A., Castleden S., et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54 (1994) 6228
66. Hall S.J., Sanford M.A., Atkinson G., et al. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 58 (1998) 3221
67. Wei C., Willis R.A., Tilton B.R., et al. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc. Natl. Acad. Sci. USA 94 (1997) 6369
68. M.V. Goldberg, C.H. Maris, E.L. Hipkiss, J.F. Grosso, T.J. Harris, D. Getnet, D.G. Brockstedt, T.W. Dubensky Jr., L. Chen, A.K. Meeker, B.J. Trock, A.M. De Marzo, T.L. DeWeese, C.G. Drake, Immunotherapy for prostate cancer: combining PD-1 checkpoint blockade with attenuated listeria-PSCA-based vaccination, 15th Spore Investigator's Meeting, 2007.
69. Bander N.H., Yao D., Liu H., et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33 (1997) 233-239
70. Rini B.I., and Small E.J. The potential for prostate cancer immunotherapy. Crit. Rev. Oncol. Hematol. 46 Suppl. (2003) S117-S125
71. Simons J.W., Mikhak B., Chang J.F., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 (1999) 5160-5168
72. Simons J.W., and Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol. Oncol. 24 (2006) 419-424
73. Tu S.M., Millikan R.E., Mengistu B., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 (2001) 336-341
74. Fong L., and Small E.J. Immunotherapy for prostate cancer. Semin. Oncol. 30 (2003) 649-658
75. Hodge J.W., McLaughlin J.P., Kantor J.A., and Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15 (1997) 759-768
76. Adis International, Prostate cancer vaccine - Northwest Biotherapeutics: CaPVax, DC1/HRPC, DCVax-Prostate, BioDrugs 16 (2002) 226-227.
77. Vihko P., Virkkunen P., Henttu P., et al. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett. 236 (1988) 275-281
78. Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18 (2000) 3894-3903
79. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24 (2006) 3089-3094
80. Sipuleucel T. APC 8015, APC-8015, prostate cancer vaccine - Dendreon. Drugs R. D. 7 (2006) 197-201
81. Canil C.M., Moore M.J., Winquist E., et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada - Clinical Trials Group. J. Clin. Oncol. 23 (2005) 455-460
82. Ziada A., Barqawi A., Glode L.M., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60 (2004) 332-337
83. G. Gravis, A. Goncalves, F. Bladou, et al., A phase II study of erlotinib in advanced prostate cancer, in: Proceedings of 2006 Prostate Cancer Symposium, 2006, p. 216.
84. Signoretti S., Montironi R., Manola J., et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92 (2000) 1918-1925
85. Solit D.B., and Rosen N. Targeting HER2 in prostate cancer: where to next?. J. Clin. Oncol. 25 (2007) 241-243
86. de Bono J., Bellmunt J., Attard G., et al. An open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 25 (2007) 257-262
87. Franklin M.C., Carey K.D., Vajdos F.F., et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004) 317-328
88. Miyamoto H., Altuwaijri S., Cai Y., Messing E.M., and Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol. Carcinog. 44 1 (2005) 1-10
89. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18 5 (2000) 1135-1149
90. Somlyo A.V., Phelps C., Dipierro C., Eto M., Read P., Barrett M., Gibson J.J., Burnitz M.C., Myers C., and Somlyo A.P. Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J. 17 2 (2003) 223-234
91. Lokeshwar B.L. MMP inhibition in prostate cancer. Ann. NY Acad. Sci. 878 30 (1999) 271-289
92. Matzkin H., Perito P.E., and Soloway M.S. Prognostic factors in metastatic prostate cancer. Cancer 72 (1993) 3788-3792
93. Singh D., Febbo P.G., Ross K., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1 (2002) 203-209
94. Uehara H., Kim S.J., Karashima T., et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst. 95 (2003) 458-470
95. Rao K., Goodin S S., Levitt M.J., et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62 (2005) 115-122
96. Mathew P., Thall P.F., Jones D., et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J. Clin. Oncol. 22 (2004) 3323-3329
97. Figg W.D., Kruger E.A., Price D.K., et al. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest. New Drugs 20 (2002) 183-194
98. Kaushal V., Mukunyadzi P., Dennis R.A., et al. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin. Cancer Res. 11 (2005) 584-593
99. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
100. Berry W., and Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 10 Suppl. 3 (2005) 30-39
101. Berges R.R., Vukanovic J., Epstein J.L., CarMichel M., Cisek L., Johnson D.E., Veltri R.W., Walsh P.C., and Isaacs J.T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1 (1995) 473-4780
102. Marini P., Denzinger S., Schiller D., Kauder S., Welz S., Humphreys R., Daniel P.T., Jendrossek V., Budach W., and Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25 (2006) 5145-5154
103. Ray S., Bucur O., and Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10 (2005) 1411-1418
104. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., and Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305 (2004) 1471-1474
105. Mackler N.J., and Pienta K.J. Drug insight: use of docetaxel in prostate and urothelial cancers. Nat. Clin. Pract. Urol. 2 (2005) 92-100
106. Pruthi R.S., Derksen E., and Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors. J. Urol. 169 (2003) 2352-2359
107. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F., and Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164 (2000) 820-825
108. Basler J.W., and Piazza G.A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J. Urol. 171 (2004) S59-S62
109. Adhami V.M., Malik A., Zaman N., Sarfaraz S., Siddiqui I.A., Syed D.N., Afaq F., Pasha F.S., Saleem M., and Mukhtar H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 13 (2007) 1611-1619
110. Moon C., and Logothetis C. Endocrine aspect of prostate cancer. Principles and Practice of Endocrinology and Metabolism (2001), Lippincott Williams and Wilkins p. 225